Tag: Epeius
Landmark Publication Confirms Rexin-G Effectively Targets Metastatic Cancers and Improves Patient Survival
SAN MARINO, Calif. -- Epeius Biotechnologies (www.epeiusbiotech.com) stuns the medical and scientific communities with a dramatic demonstration of single-agent efficacy with its lead product,...
Epeius Rexin-G Receives FDA Fast Track Designation for the Treatment of Pancreatic Cancer
SAN MARINO, Calif. -- Epeius Biotechnologies (www.epeiusbiotech.com) announced today that its lead product, Rexin-G, has been granted Fast Track designation by the U.S. Food...
The World's Smallest Hero! Epeius Bio's Rexin-G, Targeted Therapy for Metastatic Cancers
SAN MARINO, Calif. -- Epeius Biotechnologies' Rexin-G® is the world's smallest hero (epeiusbiotech.com). Imagine if you will, a tiny particle that can travel freely...
Epeius' Rexin-G Controls Tumor Growth and Improves Survival in Chemotherapy-Resistant Sarcoma and Osteosarcoma
SAN MARINO, Calif. -- Epeius Biotechnologies (www.epeiusbiotech.com) today announced the results of two related studies using Rexin-G, a tumor-targeted anti-cancer agent designed to seek-out...
Epeius Biotechnologies Rexin-G® for Metastatic Cancer Highlighted by National Cancer Institute Journal
SAN MARINO, Calif. -- Epeius Biotechnologies Corporation today announced that Rexin-G, its lead product in development for metastatic cancer, has been highlighted in a...
FDA Grants Epeius Biotechnologies Rexin-G® A Third Orphan Drug Designation
SAN MARINO, Calif. -- Epeius Biotechnologies Corporation today announced that Rexin-G has been granted Orphan Drug Designation by the U.S. Food and Drug Administration...
Epeius Biotechnologies' Tumor-Targeted Rexin-G Receives FDA Orphan Drug Designation for The Treatment of Osteosarcoma
SAN MARINO, Calif. -- Epeius Biotechnologies Corporation today announced that Rexin-G has been granted Orphan Drug Designation by the U.S. Food and Drug Administration...
TARGETED GENE DELIVERY IN VIVO: Rexin-G Monotherapy Reveals Significant Biological Activity without Toxicity
SAN MARINO, Calif. -- Epeius Biotechnologies announced today the promising results of an on-going United States-based Phase I/II study of Rexin-G for metastatic breast...
